Parsons L. Novavax reports promising phase 1 results for coronavirus vaccine. PMLiVE 2020:5 de agosto. [Ref.ID 103702]

Parsons L. AZ/Oxford’s COVID-19 vaccine proves promising in early trials. Vaccine candidate produced robust immune response. PMLiVE 2020:21 de julio. [Ref.ID 103692]

Folegatti PM, Ewer KJ, Aley PK, Angus B, Becker S, Belij-Rammerstorfer S, et al.. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 2020:20 de julio. [Ref.ID 103690]

Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough P, Chappell JD, Denison MR, Stevens LJ, Pruijssers AJ, McDermott A, et al. for the mRNA-1273 Study Group. An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. N Engl J Med 2020:14 de julio. [Ref.ID 103684]

Mullard A. COVID-19 vaccine development pipeline gears up. Lancet 2020:6 de junio. [Ref.ID 103658]

PMG Group. Imperial College London pledges low-cost access to COVID-19 vaccine. PMLiVE 2020:8 de junio. [Ref.ID 103657]

Taylor P. Novavax COVID-19 vaccine bags record $384m funding from CEPI. PMLiVE 2020:12 de mayo. [Ref.ID 103623]

Corbella J. La primera vacuna de la Covid ensayada en personas muestra eficacia. La Vanguardia 2020:19 de mayo. [Ref.ID 103619]

Samper E. Lo que el dinero no puede acelerar: ¿Por qué requiere tanto tiempo conseguir una vacuna contra el coronavirus? . eldiario.es 2020:9 de mayo. [Ref.ID 103617]

PM Group. Developing a COVID-19 vaccine. PMLiVE 2020:28 de abril. [Ref.ID 103606]

PMG Group. Moderna submits application to advance coronavirus vaccine testing. PMLiVE 2020:28 de abril. [Ref.ID 103605]

Abrams DI, Guzmán M. Can cannabis cure cancer?1. JAMA Oncology 2020:1. [Ref.ID 103508]

Desjardins A, Gromeier M, Herndon II JE, Beaubier N, Bolognesi DP, Friedman AH, Friedman HS, McSherry F, Muscat AM, Nair S, Peters KB, Randazzo D, Sampson JH, Vlahovic G, Harrison WT, McLendon RE, Ashley D, Bigner DD. Recurrent glioblastoma treated with recombinant poliovirus. N Engl J Med 2018;379:12 de juliol. [Ref.ID 102734]

Feuerstein A. Juno Therapeutics could shake up CAR-T market with strong lymphoma data. STAT 2017:1. [Ref.ID 102111]

Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon Ch, Harden M, Lennon N, Gabriel S, Rodig S, Barouch DH, Aster JC, Getz G, Wucherpfennig K, Neuberg D, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 2017;547:217-21. [Ref.ID 101662]

Pfeffer MA, McMurray JJV. Lessons in uncertainty and humility — Clinical trials involving hypertension. N Engl J Med 2016;375:1756-66. [Ref.ID 100966]

Anónimo. Alzheimer’s researchers optimistic after positive results from phase I clinical trial of aducanumab. DIA Daily 2016:3. [Ref.ID 100832]

Dal-Ré R. Desarrollo clínico de nuevos medicamentos. Seguridad de los ensayos clínicos en voluntarios sanos. Med Clin (Barc) 2016;147:154-6. [Ref.ID 100648]

Anónimo. FDA grants Biogen fast-track designation for Alzheimer’s drug. Kaiser Health News 2016:1. [Ref.ID 100625]

Anónimo. Aducanumab shows encouraging results as Alzheimer’s treatment in early clinical trial. DIA Daily 2016:3. [Ref.ID 100617]